Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Artículo
|
![]() |
Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysisSerpa Neto, A ; Tobias-Machado, M ; Esteves, M A P ; Senra, M D ; Wroclawski, M L ; Fonseca, F L A ; Dos Reis, R B ; Pompeo, A C L ; Giglio, A DProstate cancer and prostatic diseases, 2012-03, Vol.15 (1), p.36-44 [Revista revisada por pares]England: Nature Publishing GroupTexto completo disponible |
2 |
Material Type: Artículo
|
![]() |
Trends in overall survival and costs of multiple myeloma, 2000-2014Fonseca, R ; Abouzaid, S ; Bonafede, M ; Cai, Q ; Parikh, K ; Cosler, L ; Richardson, PLeukemia, 2017-09, Vol.31 (9), p.1915-1921 [Revista revisada por pares]England: Nature Publishing GroupTexto completo disponible |
3 |
Material Type: Artículo
|
![]() |
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trialREEDER, C. B ; REECE, D. E ; ZEPEDA, Vhj ; MIKHAEL, J. R ; LEIS, J. F ; BERGSAGEL, P. L ; FONSECA, R ; STEWART, A. K ; KUKRETI, V ; CHEN, C ; TRUDEL, S ; HENTZ, J ; NOBLE, B ; PIROOZ, N. A ; SPONG, J. E ; PIZA, J. GLeukemia, 2009-07, Vol.23 (7), p.1337-1341 [Revista revisada por pares]Avenel, NJ: Nature Publishing GroupTexto completo disponible |
4 |
Material Type: Artículo
|
![]() |
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myelomaCHNG, W.-J ; HUANG, G. F ; CHUNG, T. H ; NG, S. B ; GONZALEZ-PAZ, N ; TROSKA-PRICE, T ; MULLIGAN, G ; CHESI, M ; BERGSAGEL, P. L ; FONSECA, RLeukemia, 2011-06, Vol.25 (6), p.1026-1035 [Revista revisada por pares]Avenel, NJ: Nature Publishing GroupTexto completo disponible |
5 |
Material Type: Artículo
|
![]() |
Predicting multiple myeloma disease activity by analyzing natural calcium isotopic compositionGordon, G W ; Monge, J ; Channon, M B ; Wu, Q ; Skulan, J L ; Anbar, A D ; Fonseca, RLeukemia, 2014-10, Vol.28 (10), p.2112-2115 [Revista revisada por pares]England: Nature Publishing GroupTexto completo disponible |
6 |
Material Type: Artículo
|
![]() |
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working GroupFernández de Larrea, C ; Kyle, R A ; Durie, B G M ; Ludwig, H ; Usmani, S ; Vesole, D H ; Hajek, R ; San Miguel, J F ; Sezer, O ; Sonneveld, P ; Kumar, S K ; Mahindra, A ; Comenzo, R ; Palumbo, A ; Mazumber, A ; Anderson, K C ; Richardson, P G ; Badros, A Z ; Caers, J ; Cavo, M ; LeLeu, X ; Dimopoulos, M A ; Chim, C S ; Schots, R ; Noeul, A ; Fantl, D ; Mellqvist, U-H ; Landgren, O ; Chanan-Khan, A ; Moreau, P ; Fonseca, R ; Merlini, G ; Lahuerta, J J ; Bladé, J ; Orlowski, R Z ; Shah, J JLeukemia, 2013-04, Vol.27 (4), p.780-791 [Revista revisada por pares]England: Nature Publishing GroupTexto completo disponible |
7 |
Material Type: Artículo
|
![]() |
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myelomaFONSECA, R ; VAN WIER, S. A ; PRICE-TROSKA, T ; HENDERSON, K. J ; AHMANN, G. J ; GERTZ, M. A ; CHNG, W. J ; KETTERLING, R ; LACY, M. Q ; DISPENZIERI, A ; BERGSAGEL, P. L ; RAJKUMAR, S. V ; GREIPP, P. R ; LITZOW, M. RLeukemia, 2006-11, Vol.20 (11), p.2034-2040 [Revista revisada por pares]London: Nature PublishingTexto completo disponible |
8 |
Material Type: Artículo
|
![]() |
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapySTEWART, A. K ; BERGSAGEL, P. L ; WITZIG, T. E ; ZELDENRUST, S. R ; DINGLI, D ; REEDER, C. B ; ROY, V ; KYLE, R. A ; RAJKUMAR, S. V ; FONSECA, R ; GREIPP, P. R ; DISPENZIERI, A ; GERTZ, M. A ; HAYMAN, S. R ; KUMAR, S ; LACY, M. Q ; LUST, J. A ; RUSSELL, S. JLeukemia, 2007-03, Vol.21 (3), p.529-534 [Revista revisada por pares]London: Nature PublishingTexto completo disponible |
9 |
Material Type: Artículo
|
![]() |
Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trialAilawadhi, S ; Mikhael, J R ; LaPlant, B R ; Laumann, K M ; Kumar, S ; Roy, V ; Dingli, D ; Bergsagel, P L ; Buadi, F K ; Rajkumar, S V ; Fonseca, R ; Gertz, M A ; Kapoor, P ; Sher, T ; Hayman, S R ; Stewart, A K ; Dispenzieri, A ; Kyle, R A ; Gonsalves, W I ; Reeder, C B ; Lin, Y ; Go, R S ; Leung, N ; Kourelis, T ; Lust, J A ; Russell, S J ; Chanan-Khan, A A ; Lacy, M QLeukemia, 2018-03, Vol.32 (3), p.719-728 [Revista revisada por pares]England: Nature Publishing GroupTexto completo disponible |
10 |
Material Type: Artículo
|
![]() |
Pomalidomide (CC4047) plus low dose dexamethasone (Pom dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)LACY, M. Q ; HAYMAN, S. R ; ZELDENRUST, S ; FONSECA, R ; BERGSAGEL, P. L ; ROY, V ; MIKHAEL, J. R ; STEWART, A. K ; LAUMANN, K ; ALLRED, J. B ; MANDREKAR, S. J ; RAJKUMAR, S. V ; GERTZ, M. A ; BUADI, F ; SHORT, K. D ; DISPENZIERI, A ; KUMAR, S ; GREIPP, P. R ; LUST, J. A ; RUSSELL, S. J ; DINGLI, DLeukemia, 2010-11, Vol.24 (11), p.1934-1939 [Revista revisada por pares]Avenel, NJ: Nature Publishing GroupTexto completo disponible |